Parallel synthesis and screening of peptide conjugates.
Peptide conjugates represent an emerging class of therapeutics. However, in contrast to that of small molecules and peptides, the discovery and optimization of peptide conjugates is low in throughput, resource intensive, time-consuming, and based on educated decisions rather than screening. A strategy for the parallel synthesis and screening of peptide conjugates is presented that (1) reduces variability in the conjugation steps; (2) provides a new method to rapidly and quantitatively measure conversion in crude conjugation mixtures; (3) introduces a purification step using an immobilized chemical scavenger that does not rely on protein-specific binding; and (4) is supported by robust analytical methods to characterize the large number of end products. Copper-free click chemistry is used as the chemoselective ligation method for conjugation and purification. The productivity in the generation and screening of peptide conjugates is significantly improved by applying this strategy as is demonstrated by the optimization of the anti-Angiopoietin-2 (Ang2) CovX-body, CVX-060, a peptide-antibody scaffold conjugate that has advanced in clinical trials for oncology indications.
Pfizer Inc. - CovX Research, 9381 Judicial Drive, San Diego, California 92121, United States.
Anouk
A
Dirksen
Mark
M
Madsen
Giuseppe
G
Dello Iacono
Marla J
MJ
Matin
Michael
M
Bacica
Nebojša
N
Stanković
Sherri
S
Callans
Abhijit
A
Bhat
D000906:Antibodies / Q000737:chemistry; D057930:Click Chemistry; D015394:Molecular Structure; D010455:Peptides / Q000138:chemical synthesis* / Q000737:chemistry / Q000302:isolation & purification
D000906:Antibodies; D010455:Peptides